- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
October 9th, 2006
Delivering on Nano's Promise
Several nanotechnology-enabled drugs are on the market and researchers are investigating the next generation of nanoparticles for drug delivery.
In 1995, several years before the word nanotechnology began creating a buzz, Doxil (doxorubicin HCL liposome injection) received accelerated approval for the treatment of chemotherapy-refractive AIDS-related Kaposiís sarcoma. The fact that Doxil was a reformulation of an earlier drug, Adriamycin (doxorubicin), did not make it unique. What did, however, was how it was reformulated by Doxilís developer, Alza Corp., Mountain View, Calif., a subsidiary of Johnson & Johnson, New Brunswick, N.J.
|Related News Press|
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
Soft decoupling of organic molecules on metal June 23rd, 2016
Russiaís Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010